Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal

Area of Science:

• Hematology
• Pharmacology
• Clinical Medicine

Background:

• Warfarin anticoagulation requires effective reversal agents for managing major bleeding or urgent procedures.
• Four-factor prothrombin complex concentrate (4F-PCC) is a key agent for warfarin reversal.
• Dosing strategies for 4F-PCC, fixed-dose versus variable-dose, warrant comparative analysis for optimal clinical outcomes.

Purpose of the Study:

• To compare the hemostatic efficacy rates of fixed-dose versus variable-dose four-factor prothrombin complex concentrate (4F-PCC) in patients undergoing warfarin reversal.
• To evaluate secondary outcomes including INR normalization, mortality, administration time, and cost-effectiveness.

Main Methods:

• Retrospective study analyzing 265 patients receiving 4F-PCC for warfarin reversal (Sept 2013-Aug 2020).
• Hemostatic efficacy assessed at 48 hours using modified ISTH criteria for major bleeding.
• Logistic regression identified factors associated with hemostatic efficacy.

Main Results:

• Fixed-dose 4F-PCC demonstrated significantly higher hemostatic efficacy (37.8%) compared to variable-dose (21.7%), p=0.005.
• No significant difference in achieving INR ≤ 1.5 (62.5% vs 69.4%, p=0.26) or in-hospital mortality.
• Fixed-dose resulted in a mean 20-minute faster administration and $1881/dose cost reduction.

Conclusions:

• Fixed-dose 4F-PCC is associated with a higher likelihood of achieving hemostatic efficacy for warfarin reversal.
• The fixed-dose strategy offers advantages in terms of quicker administration and reduced healthcare costs.
• These findings support the use of fixed-dose 4F-PCC in clinical practice for warfarin reversal.